Iduronate-2-sulfatase regulatory update

TKTX received European and U.S. Orphan Drug designation for its iduronate-2-sulfatase (I2S) niche protein product to treat Hunter syndrome. The product is in Phase I/II trials. Hunter syndrome is a ge...